A New VISTA on combination therapy for negative checkpoint regulator blockade

Negative checkpoint regulators function to restrain T cell responses to maintain tolerance and limit immunopathology. However, in the setting of malignancy, these pathways work in concert to promote immune-mediate escape leading to the development of a clinically overt cancer. In the recent years, c...

Full description

Saved in:
Bibliographic Details
Published in:Journal for immunotherapy of cancer Vol. 4; no. 1; p. 86
Main Authors: Deng, Jie, Le Mercier, Isabelle, Kuta, Anna, Noelle, Randolph J.
Format: Journal Article
Language:English
Published: London BMJ Publishing Group Ltd 20.12.2016
BioMed Central
BioMed Central Ltd
BMJ Publishing Group LTD
BMJ Publishing Group
Subjects:
ISSN:2051-1426, 2051-1426
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Negative checkpoint regulators function to restrain T cell responses to maintain tolerance and limit immunopathology. However, in the setting of malignancy, these pathways work in concert to promote immune-mediate escape leading to the development of a clinically overt cancer. In the recent years, clinical trials demonstrating the efficacy of blocking antibodies against these molecules have invigorated the field of immunotherapy. In this review, we discuss the current understanding on established NCR blockade and how strategic combination therapy with anti-VISTA antibody can be used to target multiple non-redundant NCR pathways.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:2051-1426
2051-1426
DOI:10.1186/s40425-016-0190-5